跳至主要内容
临床试验/NCT03484286
NCT03484286已完成不适用

Selfcare Management Intervention in Heart Failure

Lund University2 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2018年4月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
124
试验地点
2
主要终点
Self-care behaviour

研究概览

简要总结

A novel tool for self-care enhancement for heart failure (HF) patients has been developed. In this randomized controlled trial, patients will be randomized 1:1 to either receive the home-based tool (OPTILOGG) or standard care. The intervention will go on for 8 months, and outcomes are self-care, cardiovascular events (including emergency visits, admissions, number of in-hospital days).

详细描述

Patients will be recruited using continuous sampling, and will be approached either in connection with being discharged after a heart failure (HF) related event or upon visiting an out-patient HF clinic if the patient has been admitted for HF at least once the last year.

After written consent has been given, demographical data will be noted, and the patient will complete forms: the European Heart Failure Self-care Behaviour scale 9-item questionnaire (EHFScB-9) and self-assessment of symtoms (NYHAclass). Expected time for this is 20 minutes. The baseline demographical data will include age, gender, ejection-fraction, New York Heart Association (NYHA)-class, blood pressure, heart rate, HF aetiology, and other routine tests for HF visits as outlined in the European guidelines for HF treatment.

After the patient has filled out the forms, the patient will be randomized to the control group (CG) meaning standard care, or the intervention group (IG). Patients allocated to the IG will be equipped with the home based self-care enhancement tool OPTILOGG. OPTILOGG assists the patient with symptom monitoring and flexible diuretics regimen, as well as education about living with HF. It consists of a specialized tablet computer wirelessly connected to a weight scale. OPTILOGG is CE-marked. The intervention will be deployed for eight months. After the eight months, the patients will be called to a follow-up visit. During the visit all data that was collected at baseline/recruitment will be collected again. All cardiovascular events for each patient will be retrieved, for the eight months during which the intervention was deployed, but also for the following 12 months. These events include hospital admissions, ER-visits and number of in-hospital days.

Based off of previous findings in the literature, target for enrollment was set at 70 + 70 patients, to achieve statistical significance with 80% power.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Outcomes Assessor)

盲法说明

Cardiovascular events will be adjudicated as heart failure related or not.

Data analysis will be performed by staff blinded to the patients IDs.

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosed heart failure, International classification of diseases (ICD): I50, existing or de-novo, in NYHA-class II-IV
  • Admission for HF within the last 12 months
  • Filled out consent form
  • Expected to be able to use the tool, if allocated to the intervention group

排除标准

  • Decline to participate
  • More than mild cognitive impairment
  • Expectancy of life < 8 months
  • For other reasons deemed inappropriate to be enrolled, e.g. participating in another study affecting standard care

结局指标

主要结局

Self-care behaviour

时间窗: Eight months

Registered using the European Heart Failure Self-care Behaviour Scale (EHFScB), a validated instrument for measuring heart failure (HF) self-care behaviour. The questionnaire is made up of 9 items, where the respondent can choose between 5 different answers to each of the 9 statements. Each item thus generates a score between 1 and 5. The total score for the instrument is between 9 and 45, with 9 constituting the best, or most desireable self-care behaviour and 45 the worst. Data will be analyzed on a group level using Mann-Whitney-U test for independent samples.

次要结局

  • Number of HF related days in the hospital(Eight months)
  • Event-free survival(Eight months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sofia Gerward

Principal Investigator, MD, PhD

Lund University

研究点 (2)

Loading locations...

相似试验